Anticalins in Drug Development Steffen SchlehuberArne Skerra Drug Development 15 August 2012 Pages: 279 - 288
Toward Personalized Immunotherapy for Non-Hodgkin Lymphoma Anne C. ArmstrongEleanor J. CheadleRobert E. Hawkins Mechanisms and Targets 15 August 2012 Pages: 289 - 297
Mechanisms of Action for Treatments in Multiple Sclerosis Michel Chofflon Mechanisms and Targets 15 August 2012 Pages: 299 - 308
The Role of Radioimmunotherapy with Yttrium- 90 Ibritumomab Tiuxetan in the Treatment of Non-Hodgkin Lymphoma Bruce D. Cheson Therapy Review 15 August 2012 Pages: 309 - 322
Spotlight on Subcutaneous Recombinant Interferon-β-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis David MurdochKatherine A. Lyseng-Williamson Adis Spotlight 15 August 2012 Pages: 323 - 325
Darbepoetin Alfa Dean M. RobinsonStephanie E. Easthope Adis Drug Evaluation 15 August 2012 Pages: 327 - 343